{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:00:35Z","timestamp":1780534835727,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R34AR075283"],"award-info":[{"award-number":["R34AR075283"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R34AR075283"],"award-info":[{"award-number":["R34AR075283"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although hydroxychloroquine (HCQ) is a mainstay of treatment for patients with systemic lupus erythematosus (SLE), ocular toxicity can result from accumulated exposure. As the longevity of patients with SLE improves, data are needed to balance the risk of ocular toxicity and the risk of disease flare, especially in older patients with quiescent disease. Accordingly, this study was initiated to examine the safety of HCQ withdrawal in older SLE patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were obtained by retrospective chart review at three major lupus centers in New York City. Twenty-six patients who discontinued HCQ and thirty-two patients on HCQ matched for gender, race\/ethnicity, and age were included in this study. The primary outcome was the occurrence of a lupus flare classified by the revised version of the Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Flare composite index, within 1\u00a0year of HCQ withdrawal or matched time of continuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five patients (19.2%) in the HCQ withdrawal group compared to five (15.6%) in the HCQ continuation group experienced a flare of any severity (odds ratio [OR]\u2009=\u20091.28; 95% CI 0.31, 5.30;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.73). There were no severe flares in either group. The results were similar after adjusting for length of SLE, number of American College of Rheumatology criteria, low complement levels, and SELENA-SLEDAI score, and in a propensity score analysis (OR\u2009=\u20091.18; 95% CI 0.23, 6.16;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.84). The analysis of time to any flare revealed a non-significant earlier time to flare in the HCQ withdrawal group (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u20090.67). Most flares were in the cutaneous and musculoskeletal systems, but one patient in the continuation group developed pericarditis. The most common reason for HCQ withdrawal was retinal toxicity (42.3%), followed by patient\u2019s preference (34.6%), other confirmed or suspected adverse effects (15.4%), ophthalmologist recommendation for macular degeneration (3.8%), and rheumatologist recommendation for quiescent SLE (3.8%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective study of older stable patients with SLE on long-term HCQ, withdrawal did not significantly increase the risk of flares.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-020-02282-0","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T07:03:45Z","timestamp":1597647825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study"],"prefix":"10.1186","volume":"22","author":[{"given":"Ruth","family":"Fernandez-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bornkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Askanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zezon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-E","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Michael","family":"Belmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lockshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill P.","family":"Buyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-2182","authenticated-orcid":false,"given":"Peter M.","family":"Izmirly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"2282_CR1","doi-asserted-by":"crossref","unstructured":"Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med, 1991. 324(3): p. 150\u20134.","DOI":"10.1056\/NEJM199101173240303"},{"issue":"11","key":"2282_CR2","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1002\/art.22159","volume":"54","author":"ME Clowse","year":"2006","unstructured":"Clowse ME, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640\u20137.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2282_CR3","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2009.119263","volume":"69","author":"PM Izmirly","year":"2010","unstructured":"Izmirly PM, et al. Evaluation of the risk of anti-SSA\/Ro-SSB\/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis. 2010;69(10):1827\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2282_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.111.089268","volume":"126","author":"PM Izmirly","year":"2012","unstructured":"Izmirly PM, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA\/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126(1):76\u201382.","journal-title":"Circulation"},{"issue":"12","key":"2282_CR5","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1136\/annrheumdis-2018-213718","volume":"77","author":"J Barsalou","year":"2018","unstructured":"Barsalou J, et al. Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Ann Rheum Dis. 2018;77(12):1742\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2282_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jacc.2020.05.045","volume":"76","author":"P Izmirly","year":"2020","unstructured":"Izmirly P, et al. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA\/Ro-positive mothers. J Am Coll Cardiol. 2020;76(3):292\u2013302.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2282_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1191\/0961203302lu203ra","volume":"11","author":"Y Molad","year":"2002","unstructured":"Molad Y, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus. 2002;11(6):356\u201361.","journal-title":"Lupus"},{"issue":"5","key":"2282_CR8","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/art.21039","volume":"52","author":"BJ Fessler","year":"2005","unstructured":"Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473\u201380.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2282_CR9","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/art.24538","volume":"61","author":"GJ Pons-Estel","year":"2009","unstructured":"Pons-Estel GJ, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830\u20139.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2282_CR10","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/art.1780301219","volume":"30","author":"DJ Wallace","year":"1987","unstructured":"Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum. 1987;30(12):1435\u20136.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2282_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3109\/03009749609069986","volume":"25","author":"M Petri","year":"1996","unstructured":"Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol. 1996;25(4):191\u20133.","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"2282_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/rheumatology\/41.8.924","volume":"41","author":"D Erkan","year":"2002","unstructured":"Erkan D, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41(8):924\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2282_CR13","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/rheumatology\/kei014","volume":"44","author":"KT Ho","year":"2005","unstructured":"Ho KT, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford). 2005;44(10):1303\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2282_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0961203306071872","volume":"15","author":"G Ruiz-Irastorza","year":"2006","unstructured":"Ruiz-Irastorza G, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15(9):577\u201383.","journal-title":"Lupus"},{"issue":"14","key":"2282_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015030","volume":"98","author":"CY Tao","year":"2019","unstructured":"Tao CY, et al. Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(14):e15030.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2282_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/0002-9343(94)90151-1","volume":"96","author":"M Petri","year":"1994","unstructured":"Petri M, et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994;96(3):254\u20139.","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"2282_CR17","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1177\/0961203396005001051","volume":"5","author":"M Petri","year":"1996","unstructured":"Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5(Suppl 1):S16\u201322.","journal-title":"Lupus"},{"issue":"2","key":"2282_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1191\/0961203305lu2039oa","volume":"14","author":"CC Mok","year":"2005","unstructured":"Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus. 2005;14(2):106\u201312.","journal-title":"Lupus"},{"issue":"9","key":"2282_CR19","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarcon","year":"2007","unstructured":"Alarcon GS, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2282_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/art.27300","volume":"62","author":"SK Shinjo","year":"2010","unstructured":"Shinjo SK, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62(3):855\u201362.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2282_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza G, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1a","key":"2282_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/0002-9343(83)91269-X","volume":"75","author":"AH Mackenzie","year":"1983","unstructured":"Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med. 1983;75(1a):40\u20135.","journal-title":"Am J Med"},{"issue":"7","key":"2282_CR23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0161-6420(03)00409-3","volume":"110","author":"I Mavrikakis","year":"2003","unstructured":"Mavrikakis I, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110(7):1321\u20136.","journal-title":"Ophthalmology"},{"issue":"6","key":"2282_CR24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/acr.20133","volume":"62","author":"F Wolfe","year":"2010","unstructured":"Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62(6):775\u201384.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"2282_CR25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"RB Melles","year":"2014","unstructured":"Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453\u201360.","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"2282_CR26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","volume":"41","author":"C Chatre","year":"2018","unstructured":"Chatre C, et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41(10):919\u201331.","journal-title":"Drug Saf"},{"issue":"5","key":"2282_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.semarthrit.2003.09.012","volume":"33","author":"JE Nord","year":"2004","unstructured":"Nord JE, et al. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum. 2004;33(5):336\u201351.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2282_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/2048872612471215","volume":"2","author":"E Joyce","year":"2013","unstructured":"Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care. 2013;2(1):77\u201383.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"12","key":"2282_CR29","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.cjca.2014.08.016","volume":"30","author":"H Yogasundaram","year":"2014","unstructured":"Yogasundaram H, et al. Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol. 2014;30(12):1706\u201315.","journal-title":"Can J Cardiol"},{"issue":"10","key":"2282_CR30","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/art.40192","volume":"69","author":"PM Izmirly","year":"2017","unstructured":"Izmirly PM, et al. The incidence and prevalence of systemic lupus erythematosus in New York County (Manhattan), New York: the Manhattan lupus surveillance program. Arthritis Rheumatol. 2017;69(10):2006\u201317.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"2282_CR31","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1002\/art.40191","volume":"69","author":"M Dall'Era","year":"2017","unstructured":"Dall'Era M, et al. The incidence and prevalence of systemic lupus erythematosus in San Francisco County, California: the California lupus surveillance project. Arthritis Rheumatol. 2017;69(10):1996\u20132005.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"2282_CR32","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1002\/art.38720","volume":"66","author":"ED Ferucci","year":"2014","unstructured":"Ferucci ED, et al. Prevalence and incidence of systemic lupus erythematosus in a population-based registry of American Indian and Alaska Native people, 2007-2009. Arthritis Rheumatol. 2014;66(9):2494\u2013502.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2282_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/art.38239","volume":"66","author":"SS Lim","year":"2014","unstructured":"Lim SS, et al. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the Georgia Lupus Registry. Arthritis Rheumatol. 2014;66(2):357\u201368.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"2282_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/art.38238","volume":"66","author":"EC Somers","year":"2014","unstructured":"Somers EC, et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol. 2014;66(2):369\u201378.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"2282_CR35","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2282_CR36","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677\u201386.","journal-title":"Arthritis Rheum"},{"issue":"24","key":"2282_CR37","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa051135","volume":"353","author":"M Petri","year":"2005","unstructured":"Petri M, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550\u20138.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"2282_CR38","doi-asserted-by":"publisher","first-page":"A473","DOI":"10.1136\/annrheumdis-2013-eular.1420","volume":"72","author":"MA Petri","year":"2013","unstructured":"Petri MA, et al. FRI0293 Validation of the revised SELENA flare index in systemic lupus erythematosus. Ann Rheum Dis. 2013;72(Suppl 3):A473\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2282_CR39","first-page":"2192","volume":"33","author":"MB Urowitz","year":"2006","unstructured":"Urowitz MB, et al. The effect of menopause on disease activity in systemic lupus erythematosus. J Rheumatol. 2006;33(11):2192\u20138.","journal-title":"J Rheumatol"},{"issue":"6","key":"2282_CR40","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor MF, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386\u201394.","journal-title":"Ophthalmology"},{"issue":"2","key":"2282_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ophtha.2010.11.017","volume":"118","author":"MF Marmor","year":"2011","unstructured":"Marmor MF, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415\u201322.","journal-title":"Ophthalmology"},{"key":"2282_CR42","doi-asserted-by":"publisher","first-page":"ix","DOI":"10.1016\/j.ajo.2016.03.044","volume":"166","author":"DJ Browning","year":"2016","unstructured":"Browning DJ. The prevalence of hydroxychloroquine retinopathy and toxic dosing, and the role of the ophthalmologist in reducing both. Am J Ophthalmol. 2016;166:ix\u2013xi.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"2282_CR43","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1002\/art.39194","volume":"67","author":"M Jallouli","year":"2015","unstructured":"Jallouli M, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(8):2176\u201384.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"2282_CR44","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1529-8019.2007.00131.x","volume":"20","author":"S Kalia","year":"2007","unstructured":"Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007;20(4):160\u201374.","journal-title":"Dermatol Ther"},{"issue":"1","key":"2282_CR45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/acr.23574","volume":"71","author":"SK Chen","year":"2019","unstructured":"Chen SK, et al. Lipid testing and statin prescriptions among Medicaid recipients with systemic lupus erythematosus or diabetes mellitus and the general Medicaid population. Arthritis Care Res (Hoboken). 2019;71(1):104\u201315.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"2282_CR46","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard.2010.136762","volume":"70","author":"MA Petri","year":"2011","unstructured":"Petri MA, et al. Lupus atherosclerosis prevention study (LAPS). Ann Rheum Dis. 2011;70(5):760\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2282_CR47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/art.30645","volume":"64","author":"LE Schanberg","year":"2012","unstructured":"Schanberg LE, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64(1):285\u201396.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2282_CR48","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/annrheumdis-2012-202315","volume":"73","author":"SP Ardoin","year":"2014","unstructured":"Ardoin SP, et al. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014;73(3):557\u201366.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2282_CR49","first-page":"162","volume":"32","author":"R Willis","year":"2014","unstructured":"Willis R, et al. Effects of statins on proinflammatory\/prothrombotic biomarkers and on disease activity scores in SLE patients: data from LUMINA (LXXVI), a multi-ethnic US cohort. Clin Exp Rheumatol. 2014;32(2):162\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"2282_CR50","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1002\/art.27478","volume":"62","author":"H Amuro","year":"2010","unstructured":"Amuro H, et al. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum. 2010;62(7):2073\u201385.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2282_CR51","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","volume":"73","author":"D Erkan","year":"2014","unstructured":"Erkan D, et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis. 2014;73(6):1176\u201380.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02282-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T18:46:27Z","timestamp":1723401987000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02282-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2282"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02282-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-33059\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-33059\/v2","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"1 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board (IRB) of the New York University School of Medicine (IRB approval number i17-00481). The study was conducted in accordance with the Helsinki Declaration as revised in 2013.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}